Answers are grounded in this paper and cite their sources.
Research isolates and evaluates secondary metabolites for lipase inhibition and lipid accumulation in adipocytes, suggesting potential obesity management.
The edible mushroom Pleurotus citrinopileatus Singer contains bioactive compounds that may be used for the management of obesity. Despite extensive research, secondary metabolites with lipase inhibition and suppression of lipid accumulation remain unexplored. Herein, we report the isolation, structure elucidation, and biological evaluation of secondary metabolites from the fruiting bodies of P. citrinopileatus. Based on spectroscopic analysis and a comparison with spectroscopic data reported in the literatures, six compounds were identified: ergosterol (1), cerevisterol (2), uracil (3), a diastereomeric mixture of 5'-deoxy-5'-methylaminoadenosine (4), diethylene glycol monobutyl ether (5), and tryptophan (6). Compounds 1-6 showed mild lipase inhibitory activity ranging from 1.7 to 11.3%. In contrast to a previous report, ergosterol 1 did not inhibit lipid accumulation in 3T3-L1 adipocytes at 25, 50, and 75 µM. This finding provides valuable insight about secondary metabolites from the fruiting bodies of this mushroom and reports their lipase inhibitory and anti-lipid accumulation activities.
No takes yet. Share an insight, caveat, or question.
Thongkongkaew et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: